Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide

Journal of the National Cancer Institute

Volumn 88, Issue 24, 1996, Pages 1840-1847

  Chen, Chun Lin ^a   Fuscoe, James C ^b   Liu, Qing ^c   Pui, Ching Hon ^c   Mahmoud, Hazem H ^d   Relling, Mary V ^a,e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c University of Tennessee   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CYTOTOXICITY; DNA RECOMBINATION; DRUG EFFECT; DRUG EXPOSURE; ENZYME REGULATION; GENE DELETION; GENE REARRANGEMENT; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; DNA PRIMERS; DNA, NEOPLASM; ETOPOSIDE; EXONS; GENE REARRANGEMENT; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID; MOLECULAR SEQUENCE DATA; NEOPLASMS, SECOND PRIMARY; SEQUENCE DELETION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0030448640     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.24.1840     Document Type: Article

References (55)

1. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993;7:1975-86.
2. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide [see comment citations in Medline]. J Clin Oncol 1993;11:209-17.
3. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
4. Chatterjee S, Trivedi D, Petzold SJ, Berger NA. Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines. Cancer Res 1990;50:2713-8.
5. Goto H, Shimazaki C, Tatsumi T, Yamagata N, Inaba T, Fujita N, et al. Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide? Int J Hematol 1994;60:145-9.
6. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, et al. Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70:1412-7.
7. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994; 23:86-98.
8. Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J, et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma [see comment citation in Medline). Am J Pediatr Hematol Oncol 1993;15:99-104.
9. Cleary ML. A promiscuous oncogene in acute leukemia. N Engl J Med 1993;329:958-9.
10. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992;71:691-700.
11. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R III, Patel Y, Harden A, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias [published erratum appears in Proc Natl Acad Sci U S A 1992; 89:4220]. Proc Natl Acad Sci U S A 1991; 88:10735-9.
12. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993;82:3705-11.
13. Bernard OA, Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer 1995;13:75-85.
14. Canaani E, Nowell PC, Croce CM. Molecular genetics of 11q23 chromosome translocations. Adv Cancer Res 1995;66:213-34.
15. Thirman MJ, Gill HJ, Burnett RC. Mbangkollo D, McCabe NR, Kobayashi H, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations [see comment citation in Medline]. N Engl J Med 1993;329:909-14.
16. Felix CA, Winick NJ, Negrini M, Bowman WP, Croce CM, Lange BJ. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia. Cancer Res 1993;53:2954-6.
17. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, et al. The t(4:11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992;71:701-8.
18. Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995; 9:1305-12.
19. Gu Y, Alder H, Nakamura T, Schichman SA, Prasad R, Canaani O, et al. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res 1994;54:2326-30.
20. Felix CA, Lange BJ, Hosler MR, Fertala J, Bjomsti MA. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 1995;55:4287-92.
21. Negrini M, Felix CA, Martin C, Lange BJ, Nakamura T, Canaani E, et al. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res 1993; 53:4489-92.
22. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias [published erratum appears in Nat Genet 1993;4:431]. Nat Genet 1992;2:113-8.
23. Domer PH, Fakharzadeh SS, Chen CS, Jockel J, Johansen L, Silverman GA, et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci U S A 1993;90:7884-8.
24. Gu Y, Cimino G, Alder H, Nakamura T, Prasad R, Canaani O, et al. The (4:11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc Natl Acad Sci U S A 1992;89:10464-8.
25. Height SE, Dainton MG, Kearney L, Swansbury GJ, Matutes E, Dyer MJ, et al. Acute myelomonocytic leukemia with t(10;11)(p13;q23): heterogeneity of breakpoints at 11q23 and association with recombinase activation. Genes Chromosomes Cancer 1994;11:136-9.
26. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993;363: 358-60.
27. Ross JA, Potter JD, Robison LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 1994;86:1678-80.
28. Fuscoe JC, Zimmerman LJ, Harrington-Brock K, Burnette L, Moore MM, Nicklas JA, et al. V(D)J recombinase-mediated deletion of the hprt gene in T-lymphocytes from adult humans. Mutat Res 1992;283:13-20.
29. Fuscoe JC, Zimmerman LJ, Lippert MJ, Nicklas JA. O'Neill JP, Albertini RJ. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T-lymphocytes. Cancer Res 1991;51:6001-5.
30. Kirsch IR, Morton CC, Nakahara K, Leder P. Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes. Science 1982;216:301-3.
31. Aplan PD, Chervinsky DS. Stanulla M, Burhans WC. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996;87: 2649-58.
32. Han YH, Austin MJ, Pommier Y, Povirk LF. Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J Mol Biol 1993;220:52-66.
33. Berger NA, Chatterjee S, Schmotzer JA, Helms SR. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci U S A 1991;33: 8740-3.
34. Chen CL, Fuscoe JC, Liu Q, Relling MV. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood 1996;88:2210-8.
35. Edwards A, Voss H, Rice P, Civitello A, Stegemann J, Schwager C, et al. Automated DNA sequencing of the human HPRT locus. Genomics 1990;6:593-608.
36. Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 1994; 56:503-11.
37. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-34.
38. Mathew P, Ribeiro RC, Sonnichsen D, Relling M, Pratt C, Mahmoud H, et al. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 1994;12:1452-7.
39. Cooper MA, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 1995;13:1167-9.
40. Gibbs RA, Nguyen PN, Edwards A, Civitello AB, Caskey CT. Multiplex DNA deletion detection and exon sequencing of the hypoxanthine phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics 1990;7:235-44.
41. Alexander DC. A rapid method for determining clone frequency in complex populations using PCR and the Poisson distribution. Nucleic Acids Res 1991;18:7453-4.
42. Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990;248:1517-23.
43. Tycko B, Sklar J. Chromosomal translocations in lymphoid neoplasia: a reappraisal of the recombinase model. Cancer Cells 1990;2:1-8.
44. Krawczak M, Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet 1991;86: 425-41.
45. Spitzner JR, Muller MT. A consensus sequence for cleavage by vertebrate topoisomerase II. Nucleic Acid Res 1988;16:5533-56.
46. Spitzner JR, Chung IK, Gootz TD, McGuirk PR, Muller MT. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements. Mol Pharmacol 1995;48:238-49.
47. Hesse JE, Lieber MR, Mizuuchi K, Gellert M. V(D)J recombination: a functional definition of the joining signals. Genes Dev 1989;3:1053-61.
48. Hashimoto H, Chatterjee S, Berger NA. Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1995;1:369-76.
49. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984;44:5857-60.
50. Laquerbe A, Moustacchi E, Fuscoe JC, Papadopoulo D. The molecular mechanism underlying formation of deletions in Fanconi anemia cells may involve a site-specific recombination. Proc Natl Acad Sci U S A 1995; 92:831-5.
51. Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986;25:2248-56.
52. Clark PI. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin Oncol 1992;19(2 Suppl 6):20-7.
53. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3.
54. Millward MJ, Newell DR, Yuen K, Matthews JP, Balmanno K, Charlton CJ, et al. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother Pharmacol 1995;37:161-7.
55. Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995;9:1680-4.